Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...

In a report released yesterday, Jessica Fye from J.P. Morgan maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a ...

Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 ...

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved ...

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

The Investment Committee give you their top stocks to watch for the second half.

Despite high demand for an option like Journavx, doctors fear the drug’s price could be a hangup for insurers and limit ...

Each year, about 125 million opioid prescriptions are written for Americans with pain caused by broken bones, burns, ...

Shares of Vertex Pharmaceuticals gained about 6% Friday morning, after the pharmaceutical company won U.S. approval for the ...